Monday, Sep 28, 2020 | Last Update : 06:01 PM IST

188th Day Of Lockdown

Maharashtra1339232103001535571 Andhra Pradesh6756746050905708 Tamil Nadu5808085251549313 Karnataka5755664622418582 Uttar Pradesh3870853258885594 Delhi2711142366515235 West Bengal2474252169214781 Odisha209374173571850 Telangana1872111564311107 Bihar178882164537888 Kerala175385117917678 Assam169985139977655 Gujarat1332191132403417 Rajasthan1288591077181441 Haryana1237821059901307 Madhya Pradesh117588932382207 Punjab107096840253134 Chhatisgarh9856566860777 Jharkhand7770964515661 Jammu and Kashmir69832495571105 Uttarakhand4533233642555 Goa3107125071386 Puducherry2548919781494 Tripura2412717464262 Himachal Pradesh136799526152 Chandigarh112128677145 Manipur9791760263 Arunachal Pradesh8649623014 Nagaland5768469311 Meghalaya5158334343 Sikkim2707199431 Mizoram178612880
  Science   14 Apr 2020  WHO Solidarity trial testing antiviral drug remdesivir, as it could stop coronavirus from replicating

WHO Solidarity trial testing antiviral drug remdesivir, as it could stop coronavirus from replicating

PTI
Published : Apr 14, 2020, 1:51 pm IST
Updated : Apr 14, 2020, 1:51 pm IST

In an observational study, 68 per cent or two out of three patients after treatment with the drug did not require ventilator support

In this March 2020 photo provided by Gilead Sciences, rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Photo | AP)
 In this March 2020 photo provided by Gilead Sciences, rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Photo | AP)

New Delhi: The Indian Council of Medical Research on Monday said antiviral drug remdesivir, which was used during the Ebola outbreak, may be highly effective in stopping the replication mechanism of SARS-CoV-2 that causes COVID-19.

The ICMR said research on its efficacy in the treatment of COVID-19 is a part of WHO's "Solidarity Trial".

 

According to a recently published study in the New England Journal of Medicine, two out of three critically ill coronavirus infected patients who were on oxygen support or on ventilators showed signs of improvement when they were administered remdesivir.

Commenting on the study, Head of Epidemiology and Communicable diseases at ICMR Raman R Gangakhedkar said that drug which was used against Ebola virus, according to the researchers, hinders the reproduction of coronavirus which is why they believe that it could be effective in COVID-19 treatment.

"A recently reported study on use of remdesivir for COVID-19 treatment is not a clinical trial, but an observational study which found that 68 per cent or two out of three patients after treatment with the drug did not require ventilator support or their need for oxygen support reduced. We will come to know of further developments through the WHO Solidarity Trial, which has an arm which is looking into this," he said.

 

He further said that remdesivir, developed by Gilead Sciences Inc, is not presently available in the country and the government is working on to see if  any pharmaceutical company can manufacture it.

Tags: coronavirus (covid-19), ebola, sars-cov-2, indian council of medical research (icmr), new england journal of medicine, remdesivir, who solidarity trial